Difference between revisions of "Autoimmune cytopenia"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "'''contains protocol'''" to "'''contains dosing details in abstract'''") |
Warner-admin (talk | contribs) |
||
| Line 1: | Line 1: | ||
| − | + | <span id="BackToTop"></span> | |
| − | + | <div class="noprint" style="background-color:LightGray; position:fixed; bottom:2%; right:0.25%; padding-left:5px; padding-right:5px; margin: 15px; opacity:0.8; border-style: solid; border-color:DarkGray; border-width: 1px"> | |
| − | + | [[#top|Back to Top]] | |
| − | + | </div> | |
| − | + | {{#lst:Section editor transclusions|heme}} | |
| − | |||
| − | |||
| − | |||
| − | | | ||
| − | |||
{| class="wikitable" style="float:right; margin-right: 5px;" | {| class="wikitable" style="float:right; margin-right: 5px;" | ||
|- | |- | ||
Revision as of 17:18, 1 September 2022
2 regimens on this page
2 variants on this page
|
This is an umbrella category that includes Felty's syndrome (autoimmune neutropenia), autoimmune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA), and Evan's syndrome (AIHA & ITP). Please see the respective page(s) for disease-specific therapies. This page includes regimens that were used more broadly.
Guidelines
"How I Treat"
- 2022: Porpaczy & Jäger How I manage autoimmune cytopenias in patients with lymphoid cancer
Relapsed or refractory
Alemtuzumab monotherapy
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Willis et al. 2001 | Phase 2 | ORR: 71% |
Immunosuppressive therapy
- Alemtuzumab (Campath) as follows:
- Test dose: 1 mg IV over 60 minutes once
- Days 1 to 10: 10 mg IV over 4 hours once per day
10-day course
References
- Willis F, Marsh JC, Bevan DH, Killick SB, Lucas G, Griffiths R, Ouwehand W, Hale G, Waldmann H, Gordon-Smith EC. The effect of treatment with Campath-1H in patients with autoimmune cytopenias. Br J Haematol. 2001 Sep;114(4):891-8. link to original article contains dosing details in manuscript PubMed
Sirolimus monotherapy
Regimen
| Study | Evidence | Efficacy |
|---|---|---|
| Bride et al. 2015 | Phase 2 | Durable CR observed in patients with ALPS |
Immunosuppressive therapy
- Sirolimus (Rapamune) 2 to 2.5 mg/m2/day PO
- See manuscript for recommended dose adjustments
6-month course, extended for those with a favorable response
References
- Bride KL, Vincent T, Smith-Whitley K, Lambert MP, Bleesing JJ, Seif AE, Manno CS, Casper J, Grupp SA, Teachey DT. Sirolimus is effective in relapsed/refractory autoimmune cytopenias: results of a prospective multi-institutional trial. Blood. 2016 Jan 7;127(1):17-28. Epub 2015 Oct 26. link to original article link to PMC article contains dosing details in abstract PubMed